A federal judge has banned the sale of Regeneron Pharmaceuticals' (REGN) cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen (AMGN) and its competing drug Repatha in a long-running patent lawsuit. Regeneron and Sanofi (SNY) intend to appeal both the original patent infringement decision and the judge's injunction against Praluent.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.